Rheumatology.net

Rheumatology Xagena

Cardiovascular disease ( CVD ) is the leading cause of death in rheumatoid arthritis ( RA ) patients. This study is the first to report the association of Hydroxychloroquine ( Plaquenil; an antirheuma ...


Researchers have evaluated the current evidence of the effectiveness of Botulinum toxin ( BTX ) treatment for shoulder pain. Randomized controlled trials comparing the clinical efficacy ( pain inte ...


Metabolic abnormalities are common in patients with depressive disorders. However, the relationship between gout and depression is unclear. Researchers explored the causal relationship among gout, ...


The extent of lung involvement visualized by high-resolution computed tomography ( HRCT ) is a predictor of decline in forced vital capacity ( FVC ) in scleroderma-interstitial lung disease. The obj ...


Systemic sclerosis ( SSc ) is the most severe connective tissue disorder. Recent studies have demonstrated that genetic factors may play a role in the development of systemic sclerosis. The aim of t ...


Primary Sjögren syndrome ( PSS ) is a chronic inflammatory autoimmune disease. Interstitial lung disease ( ILD ) can be an extraglandular complication. A multicentre cohort study has evaluated the ...


Kawasaki disease ( KD ) is also known as multiple mucocutaneous lymph node syndrome of systemic vasculitis and is a leading cause of coronary artery lesions ( CAL ) in childhood. Intravenous immunog ...


Takayasu's arteritis ( TAK ) is a chronic, large-vessel vasculitis. Vitamin D, as a steroidal hormone, has recently been shown to have immunoregulatory and immunosuppressive effects. Low vitamin D l ...


A study aimed to assess the relative efficacy and safety of biologics and Tofacitinib ( Xeljanz ) in patients with rheumatoid arthritis showing an inadequate response to tumor necrosis factor ( TNF ) ...


In Behcet's disease ( BD ), interleukin-6 ( IL-6 ) drive the immune-mediated inflammatory process. The IL-6 receptor can be targeted using Tocilizumab ( RoActemra ). As an off-label treatment, resea ...


Researchers have conducted a study to analyze how infection by hepatitis C virus ( HCV ) may influence the immunological serum pattern of patients with Sjögren syndrome ( SS ). Since 1994, research ...


Previous studies showed inconsistent results on the association of systemic sclerosis ( SSc ) with multiple sclerosis ( MS ), and are limited by a lack of adjustment for sex and age. The goals of th ...


Previous studies indicated that gout is a risk factor of cardiovascular diseases. This study aimed to determine if patients with gout have an increased risk of deep vein thrombosis ( DVT ) or pulmonar ...


A study has assessed the prevalence of overweight and obesity in a large cohort of patients with axial spondyloarthritis ( axSpA ) in comparison with the general population. To explore the relationshi ...


A study has evaluated the effects of aerobic exercise in patients with ankylosing spondylitis ( AS ). Seventy patients classified with ankylosing spondylitis by the modified New York criteria were ...


A study has examined the risk of atrial fibrillation ( AF ) at the time of first diagnosis of gout compared with matched controls and has followed incident gout patients and their matched controls aft ...


The aim of a study was to investigate the prevalence of monosodium urate ( MSU ) crystal deposits, indicative for gout, in a population of rheumatoid arthritis ( RA ) patients with concomitant hyperur ...


Previous studies of stroke in systemic lupus erythematosus ( SLE ) have had limited statistical power, combined stroke subtypes into composite outcomes, and lacked a reference population estimate. T ...


A study has estimated the frequency of cardiovascular events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus ( SLE ) and has investigated the main ...


The aim was to study the association between 25-hydroxyvitamin D [ 25(OH)D ] levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases ( CIRD ). Researchers s ...


A study has described the long-term adherence, efficacy, and safety in patients with psoriatic arthritis ( PsA ) treated with Etanercept ( Enbrel ) in a daily clinical setting in Belgium. The PROVE ...


Interleukin-17A ( IL-17A ) is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, Secukinumab ( Cosentyx ), a fully human anti-IL-17A monoclonal antibody ...


Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis ( PsA ) in 2012, new evidence and new therapeutic age ...


Most incident cases of psoriatic arthritis ( PsA ) present among patients with pre-existing psoriasis, and because of the high absolute prevalence of psoriatic arthritis among psoriasis patients this ...


Patients with rheumatoid arthritis ( RA ) and co-existent bronchiectasis ( BRRA ) have a five-fold increased mortality compared to rheumatoid arthritis alone. Yet previous studies have found no differ ...


Positive data from the phase IIb BALANCE-I and BALANCE-II trials for experimental JAK1 inhibitor, ABT-494 in rheumatoid arthritis were announced. The BALANCE-I study evaluated one of four twice-da ...


Stimulators of the soluble guanylate cyclase ( sGC ) have recently been shown to inhibit transforming growth factor-beta ( TGF-beta ) signalling. Researchers aimed to demonstrate that Riociguat ( ...


Enhanced cardiovascular risk in ankylosing spondylitis provides a strong rationale for early therapeutical intervention. In view of the proven benefit of statins in atherosclerotic vascular disease, a ...


Patients with rheumatoid arthritis and carotid artery plaques have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol ( LDL-c ) goal  less than or eq ...


The objective of a study was to determine the safety of Ocrelizumab in patients with rheumatoid arthritis. An analysis of the double-blind, placebo-controlled periods and long-term follow-up of 4 O ...


The results of several new sub-analyses of the phase IIIb AVERT ( Assessing Very Early Rheumatoid arthritis Treatment ) trial that investigated the use of Abatacept ( Orencia ) plus Methotrexate ( MTX ...


Rheumatoid arthritis is associated with increased cardiovascular morbidity and mortality attributed to traditional cardiovascular risk factors and/or the chronic systemic inflammation. Researchers ...


Etanercept ( Enbrel ) has been widely applied in the treatment of ankylosing spondylitis ( AS ). Previous meta-analyses have focused on comparing the differences in clinical outcomes between Etanercep ...


A study has evaluated the efficacy and safety of Adalimumab ( Humira ) in patients with juvenile idiopathic arthritis ( JIA ). Baseline demographic and clinical characteristics and disease activity ...


A study has investigated whether use of Adalimumab ( Humira ) decreases the frequency of attacks of anterior uveitis in patients with ankylosing spondylitis. Consecutive patients with ankylosing sp ...


High body mass index ( BMI ) is associated with increased risk of osteoarthritis ( OA ) and reduced risk of fragility fracture. However, the relationship between fragility fracture and osteoarthritis ...


Positive results from a phase 3 trial of investigational drug Sarilumab in rheumatoid arthritis ( RA ) patients who were inadequate responders to Methotrexate ( MTX ) therapy were presented at the Eur ...


The aim of the study was to assess efficacy and safety of TNF-alpha antagonists ( anti-TNF ) in a cohort of patients with juvenile idiopathic arthritis ( JIA ) who began treatment under 4 years old an ...


The European Commission ( EC ) has granted a licence extension for Enbrel ( Etanercept ) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis ( nr-axSpA ). Non-ra ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


A new study presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) has shown a significantly increased risk of myocardial infarction in patients with Sjögren's syndrome ( S ...


Data presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) have demonstrated the possibility of using biomarkers ( developed from whole blood gene expression profiles ) in ...


Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi ...


Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus Methotrexate or Methotrexate alone are unclear. ...


Two-year results from the ORAL Start study were published in The New England Journal of Medicine ( NEJM ). ORAL Start is a 24-month phase 3 study in patients with moderately to severely active rheumat ...


Decernotinib ( VX-509 ) is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis ( RA ). This was a 24-week, randomized, placebo-controlled, double-blind, phase 2 ...


Tofacitinib ( Xeljanz ) is an oral Janus kinase ( JAK ) inhibitor for the treatment of rheumatoid arthritis ( RA ). Phase 2, phase 3, and open-label long-term extension ( LTE ) studies have described ...


Mavrilimumab and Sifalimumab have met their primary endpoints in respective phase II studies, demonstrating further pipeline progress in core therapeutic areas. Mavrilimumab, an investigational mon ...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of adult patients with active psoriatic arth ...


The aim of a study was to describe the long-term safety and efficacy profile of Tofacitinib ( Xeljanz ) in patients with moderate to severe active rheumatoid arthritis. Data were pooled from 2 open ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati